Amgen and Cytokinetics Announce Late-Breaking Presentation of COSMIC-HF Trial at AHA Scientific Sessions 2015
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Cytokinetics (CYTK) and Amgen Inc. (AMGN) Announce COSMIC-HF Data; Roth Capital Raises Price Target to $22
November 9, 2015 7:32 AM ESTRoth Capital maintained a Buy rating on Cytokinetics (NASDAQ: CYTK), and raised the price target to $22.00 (from $18.00), following announced full data from COSMIC-HF at AHA. The large data set was announced jointly by Cytokinetics and global partner Amgen (NASDAQ:... More
Amgen (AMGN), Cytokinetics (CYTK) Announce COSMIC-HF Met Primary Endpoint
November 9, 2015 6:16 AM ESTAmgen (Nasdaq: AMGN) and Cytokinetics Incorporated (Nasdaq: CYTK) announced the presentation of data from the expansion phase of COSMIC-HF (Chronic Oral... More
